Prostatic carcinoma is one of the most frequent male cancer and the second cause of male cancer death. Therefore prostatic cancer screening are performed for a precocious cancer diagnosis and therapy and real decrease in death prostatic cancer. Actually exit two important controlled randomised studies about prostatic cancer screening. The target of the work is to understand if it is possible and effective to introduce prostatic cancer screening in clinical practice and to define costs/benefits. Unfortunately the naturale history of the prostatic cancer, the high number of patient to treat after screening studies, the high cost of the practicable therapies don't justify either the screening studies either the following therapies in all patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.